NCT04406415View on ClinicalTrials.gov

Oral Nafamostat in Healthy Volunteers (NAF-101)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

November 11, 2020

Study Completion Date

May 14, 2021

Conditions
Pharmacokinetics
Interventions
DRUG

Nafamostat Mesilate

Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days

DRUG

Placebo

Oral placebo administered three times daily for up to 5 days

Trial Locations (1)

85023

Arizona Research Center, Phoenix

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Ensysce Biosciences

INDUSTRY